Zuranolone, a neuroactive drug, used in the treatment of postpartum depression by modulation of GABA receptors.

Pharmacol Biochem Behav

Department of Pharmacy, GD Goenka University, Gurugram, Haryana 122103, India; Amity Institute of Pharmacy, Amity University, Sector - 125, Noida, Uttar Pradesh-201301, India. Electronic address:

Published: May 2024

AI Article Synopsis

  • Postpartum depression (PPD) is a common and serious mood disorder for new mothers, and zuranolone (Zurzuvae) is a new drug approved by the FDA in August 2023 specifically for its treatment.
  • The review covers zuranolone's dosing, chemistry, mechanism of action, clinical trial results, potential side effects, and its implications for treating PPD effectively.
  • While zuranolone shows promise as a treatment to alleviate the impact of PPD, ongoing studies are needed to confirm its long-term safety and effectiveness in clinical practice.

Article Abstract

Background: Postpartum depression [PPD] is a prevalent and debilitating mood disorder that affects mothers in the weeks to months after childbirth. Zuranolone (Zurzuvae) is a novel pharmaceutical agent that was approved by the US FDA on 4 August 2023 for the management of PPD. This review article provides a comprehensive overview of zuranolone, focusing on its dosing, chemistry, mechanism of action, clinical trials, adverse drug reaction, and overall conclusion regarding its utility in the management of PPD. It also discusses the recommended dosing strategies to achieve optimal efficacy while minimizing adverse effects as the dosage regimen of zuranolone is critical for its therapeutic application. Moreover, it gives insights into neurobiological pathways involved in PPD.

Methodology: Data from randomized controlled trials and observational studies was collected to provide a comprehensive understanding of zuranolone in the management and treatment of PPD.

Conclusion: Zuranolone represents a promising therapeutic option for women suffering from postpartum depression. However, ongoing research and post-marketing surveillance are essential to further elucidate its long-term safety and efficacy. The integration of zuranolone into clinical practice may significantly improve the quality of life for mothers facing the challenges of postpartum depression.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pbb.2024.173734DOI Listing

Publication Analysis

Top Keywords

postpartum depression
16
management ppd
8
zuranolone
7
zuranolone neuroactive
4
neuroactive drug
4
drug treatment
4
postpartum
4
treatment postpartum
4
depression
4
depression modulation
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!